亚洲精品国产成人一区二区_欧美性xxxxx极品娇小_国产欧美久久一区二区三区_日日麻批免费40分钟无码

Mabwell Announces the First Patient Dosed in the Clinical Studies of 2 Novel ADCs

Release time:Sep 05, 2023

Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that the first patient dosed in the Phase I/II studies for Trop-2 targeting ADC (R&D code: 9MW2921) and B7-H3 targeting ADC (R&D code: 7MW3711), respectively.

The primary objective of Phase I/II study of 9MW2921 (Register No.: CTR20232341) is to investigate the safety and tolerability, explore the maximum tolerated dose (MTD), confirm the RP2D, and preliminarily evaluate the efficacy of 7MW3711 in particular tumor types.

The primary objective of phase I/II study of 7MW3711 (Register No.: CTR20232441) is to investigate the safety, tolerability, MTD and/or RP2D, and preliminarily evaluate the efficacy of 7MW3711 in particular tumor types.

 

Trop-2 targeting ADC (9MW2921)

9MW2921 is a next generation antibody-drug conjugate (ADC) developed by Mabwell based on IDDC? platform for the treatment of solid tumors. It is an innovative antibody molecule linked to a novel payload (TOP1i) by a novel linker with fully autonomous intellectual property right. When 9MW2921 enters the body, it can specifically bind to antigens on the cell membrane surface, be internalized and trafficked to the lysosome, release cytotoxic drug, and induce the apoptosis of tumor cells.

9MW2921 is pharmaceutical characterized as stable structure, homogeneous composition, high purity, and it is suitable for industrial scale-up. Compared with ADCs of the same class under development at home and abroad, 9MW2921 is significantly improved and optimized in endocytic activity, plasma stability, drug release characteristics, bystander killing effect, etc. In vivo pharmacodynamic studies demonstrated that 9MW2921 had a better tumor killing activity. In animal safety evaluation models including cynomolgus monkeys and rats, the on-target and off-target toxicities of 9MW2921 were effectively controlled, indicating that 9MW2921 has good safety profile and pharmacokinetic properties.


B7-H3 targeting ADC (7MW3711)

The next generation antibody-drug conjugate molecule 7MW3711 with proprietary intellectual property right, developed by Mabwell's next-generation antibody-drug conjugate platform IDDC?, is composed of innovative antibody molecule, novel linker, and novel payload (TOP1i). When 7MW3711 enters human body, it specifically binds to antigens on the tumor cell membrane surface, be internalized and trafficked to the lysosome, release cytotoxic drug, and induce the apoptosis of tumor cells.

7MW3711 is pharmaceutical characterized as stable structure, homogeneous composition, high purity, and it is suitable for industrial scale-up. Compared with drugs in the same class at home and abroad, 7MW3711 has shown better tumor killing effects in multiple animal tumor models. In the safety evaluation model of animals including cynomolgus monkeys, the on-target and off-target toxicities of 7MW3711 are effectively controlled, showing its good safety profile and pharmacokinetic properties. The above research results indicate that 7MW3711 has clinical differentiation characteristics and a promising future of clinical development.

 

Next generation antibody-drug conjugate platform IDDC?

Mabwell has developed multiple ADC technology platforms, and its Nectin-4-targeting ADC (R&D code: 9MW2821) is currently in the phase II study.

IDDC? is a next generation ADC site-specific conjugate technology platform independently developed by Mabwell. It is composed of multiple systematized core patent technologies including site-specific conjugate process DARfinity?, special designed linker IDconnect?, novel payload Mtoxin?, and conditional release structure LysOnly?, which improves structural homogeneity, quality stability, pharmacodynamics and tolerability of the ADC products.

Currently, the advantage of the IDDC? platform has been validated in several products under development. Trop-2-targeting ADC (R&D code: 9MW2921) has been approved for clinical study in advanced solid tumor. It is expected multiple ADC products will enter clinical development in 2023 and 2024.

主站蜘蛛池模板: 金塔县| 东丽区| 天柱县| 金寨县| 洛浦县| 长子县| 会同县| 扎赉特旗| 县级市| 集安市| 池州市| 巴林左旗| 鄂尔多斯市| 门源| 洛浦县| 彭水| 宁波市| 隆昌县| 宝兴县| 华容县| 武宁县| 达州市| 九龙县| 会理县| 柳江县| 德令哈市| 准格尔旗| 蓬莱市| 松原市| 邯郸市| 越西县| 卫辉市| 闽侯县| 浦城县| 陕西省| 淮南市| 旬邑县| 措勤县| 新巴尔虎右旗| 城固县| 东兴市|